Mind Medicine (MNMD) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Mind Medicine has commenced its Phase 3 Voyage study, dosing the first patient with MM120, an optimized form of LSD, for treating Generalized Anxiety Disorder (GAD). This study aims to assess the drug’s efficacy and safety compared to a placebo, building on promising Phase 2b results. The company plans to enroll approximately 200 participants in the U.S., with a second trial set to start in 2025 in the U.S. and Europe.
For further insights into MNMD stock, check out TipRanks’ Stock Analysis page.
